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A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and
the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine
priming improves responses to inactivated influenza vaccines. We describe the rapid pro-
duction and clinical evaluation of a DNA vaccine encoding the hemagglutinin protein of the
2009 pandemic A/California/04/2009(H1N1) influenza virus, accomplished nearly two
months faster than production of A/California/07/2009(H1N1) licensed monovalent inacti-
vated vaccine (MIV).
Methods
20 subjects received three H1 DNA vaccinations (4 mg intramuscularly with Biojector) at
4-week intervals. Eighteen subjects received an optional boost when the licensed H1N1
MIV became available. The interval between the third H1 DNA injection and MIV boost was
3–17 weeks. Vaccine safety was assessed by clinical observation, laboratory parameters,
and 7-day solicited reactogenicity. Antibody responses were assessed by ELISA, HAI and
neutralization assays, and T cell responses by ELISpot and flow cytometry.
Results
Vaccinations were safe and well-tolerated. As evaluated by HAI, 6/20 developed positive re-
sponses at 4 weeks after third DNA injection and 13/18 at 4 weeks after MIV boost. Similar
results were detected in neutralization assays. T cell responses were detected after DNA
and MIV. The antibody responses were significantly amplified by the MIV boost, however,
the boost did not increased T cell responses induced by DNA vaccine.
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Conclusions
H1 DNA vaccine was produced quickly, was well-tolerated, and had modest immunogenici-
ty as a single agent. Other HA DNA prime-MIV boost regimens utilizing one DNA prime vac-
cination and longer boost intervals have shown significant immunogenicity. Rapid and
large-scale production of HA DNA vaccines has the potential to contribute to an efficient re-




Annually, seasonal influenza epidemics cause between 250,000 and 500,000 deaths, the majori-
ty in persons age 65 or older [1]. Licensed seasonal influenza vaccines provide only moderate
protection against influenza and take significant resources and time to manufacture each year
[2, 3].
In April 2009, a novel swine-origin influenza A (H1N1) virus (S-OIV) was identified [4]. By
June 2009, the World Health Organization (WHO) declared a global pandemic was underway
[5]. Pandemic influenza vaccine manufacturing was enabled by swift genomic identification
and Food and Drug Administration (FDA) support of strain change as a pathway for licensure
[6]. Vaccine manufacturers developed prototype vaccines by August 2009 and received FDA
approval by September 2009 (one additional vaccine was approved in November 2009) [7]. De-
spite rapid action, vaccine product was not available for the 2009 winter season in the Southern
Hemisphere [8]. The vaccines made available to the public demonstrated robust immunogenic-
ity in subsequent clinical studies [9–12]. Emergence of and experiences with the 2009 H1N1
pandemic influenza virus, as well as continued antigen evolution of known influenza strains,
together emphasize the need to streamline influenza vaccine development [13].
Plasmid DNA-based vaccines have demonstrated preclinical efficacy and a relatively rapid
manufacturing process. Plasmid DNA can be quickly modified to carry an antigen of interest,
and recombinant DNA technology allows much faster development and production of vaccine
candidates based on viral genome sequences than traditional vaccine production methods [14–
18]. Testing these potential vaccine candidates in Phase I clinical studies can rapidly provide
data on the immunogenicity of novel influenza hemagglutinins and clarify if exposure to other
influenza strains may offer some cross protection.
If the speed of a given vaccine’s development and production do not meet public demand,
regardless of its immunogenicity, that vaccine will not effectively halt a pandemic. Improving
the efficiency of vaccine production is an important aspect of influenza vaccine development
that could help to meet the demand for rapid, widespread, protective immunity during future
pandemics.
Here we report the results of a Phase 1 study evaluating the safety and immunogenicity of a
2009 pandemic H1 DNA vaccine with or without a boost of licensed pandemic H1N1 MIV
given 3–17 weeks later. The safety and immunogenicity of the investigational H1 DNA vaccine
followed by H1N1 MIV boost was evaluated.
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Methods
Study Design
The protocol for this trial and supporting CONSORT checklist are available as supporting infor-
mation; see S1 CONSORT Checklist and S1 Protocol. VRC 308 was a single-site, Phase I, open-
label clinical trial investigating the safety (primary outcome) and immunogenicity (secondary
outcome) of an investigational pandemic influenza H1 DNA vaccine, VRC-FLUDNA057-
00-VP. VRC 308 (NIH 09-I-0204, NCT00973895) was conducted at the National Institutes of
Health (NIH), Bethesda, MD by the Vaccine Research Center (VRC) with recruitment and
screening of volunteers conducted through an IRB-approved screening protocol (NIH 03-I-0285,
NCT00068926) for vaccine study volunteers. Recruitment and screening was conducted August
6, 2009 through November 3, 2009. IRB approval of protocol VRC 308 was completed August 7,
2009. Enrollment of 20 subjects occurred from August 24, 2009 through November 5, 2009. The
last VRC 308 follow-up visit was June 17, 2010. The applicable regulatory requirements and the
U.S. Department of Health and Human Services human experimental guidelines for conducting
clinical research were followed. All subjects gave written informed consent for study participa-
tion. The authors confirm that all ongoing and related trials for this drug/intervention are
registered.
Three injections of H1 DNA vaccine were administered on study days 0, 28, and 56, at a
dose of 4 mg each, intramuscularly (IM) in the deltoid muscle. The Biojector 2000 Needle-Free
Injection Management System (Bioject; Tualatin, OR, USA) was used to enhance immunoge-
nicity [19]. When pandemic monovalent inactivated vaccine (MIV) became available, it was of-
fered through a protocol amendment for administration as a booster. Subject safety was
monitored by evaluation of laboratory and clinical findings at study visits; adverse events were
coded with the Medical Dictionary for Regulatory Activities (MedDRA) and assessed for sever-
ity using a scale (0–5) developed by the Division of AIDS, NIAID, adapted for healthy volun-
teer studies. Solicited local and systemic reactogenicity symptoms were collected for 7 days
following each vaccination. Adverse events were recorded through 28 days after the final H1
DNA vaccination and, if administered, for 28 days following licensed H1N1 MIV vaccination.
Vaccines
The pandemic H1 DNA plasmid vaccine, VRC-FLUDNA057-00-VP, was manufactured at the
VRC/NIAID/Vaccine Pilot Plant operated by SAIC-Frederick (Frederick, MD) under cGMP.
The vaccine is composed of a single closed circular DNA plasmid encoding hemagglutinin
(HA) protein of the A/California/04/2009(H1N1) pandemic influenza virus under the control
of the CMV/R promoter. The insert (GenBank ACP41105) used in the Master Cell Bank
(MCB) was synthesized by VRC using Blue Heron Biotechnology, Inc. (Bothell, WA) for
human preferred codons as previously described [20]. The plasmid was used to transform the
Escherichia coli bacterial host strain, DH5α, in order to produce a Master Cell Bank (MCB).
The MCB was expanded in culture and inoculated into a 100-liter fermenter for production.
Bacterial cell growth was dependent upon the cellular expression of the kanamycin resistance
protein encoded by a portion of the plasmid DNA. Following the growth of bacterial cells ex-
pressing the plasmid, the plasmid DNA was purified from cellular components, concentrated,
filtered through a 0.22 μmmembrane, and stored until formulation of the drug product. The
drug product was filled at 4 mg/mL in phosphate buffered saline (PBS) in 3 mL vials.
Commercially available, licensed H1N1 pandemic influenza vaccine, A/California/07/2009,
manufactured by Sanofi Pasteur, Inc. (n = 2) or Novartis Vaccines and Diagnostics, Inc.
(n = 15) was administered by needle and syringe in the deltoid muscle.
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Measurement of Antibody Responses by HAI Assay
The detection of H1 antibody by HAI assay was based on previously described methods and
optimized for detection of antibodies against pandemic H1N1 influenza (A(H1N1)pdm09)
[21]. HAI assays were performed in V-bottom 96-well plates using four hemagglutinating
units (HAU) of virus and 0.5% turkey RBCs as previously described [22]. The A/Mexico/4482/
2009 H1N1 virus strain that is genetically and antigenically similar to the prototype A(H1N1)
pdm09 vaccine virus, A/California/04/2009(H1N1), was used in the HAI assay performed at
the CDC Influenza Branch (Atlanta, GA) [23, 24]. A response was assessed as positive at base-
line (pre-vaccination) if the titer was 10 or greater, If the subject was negative at baseline, the
post-vaccination titer was assessed as positive if the value was 40 or greater. If the subject was
positive at baseline, the post-vaccination titer was assessed as positive if value was at least a
4-fold increase in titer from baseline.
Measurement of Antibody Responses by ELISA
End-point titers of antibodies directed against H1 A/California/04/2009(H1N1) antigen (Pro-
tein Sciences Corporation, Meriden, CT) were determined using 96-well Immulon2 (Dynex
Technologies) plates coated with a preparation of purified recombinant protein according to
methods adapted from those previously described [25]. End-point titer was calculated as the
most dilute serum concentration that gave an optical density reading of>0.2 above back-
ground. An ELISA endpoint titer was assessed as positive if the value, after subtraction of the
baseline pre-vaccination value, was greater than or equal to 30.
Measurement of Neutralizing Antibody Responses
A/California/04/2009(H1N1) neutralizing antibodies were evaluated by the capacity of sera to
prevent the infection of 293A cells by replication-incompetent HA-pseudotyped virus. The
pseudotyped virus expressed the HA and NA antigens of A/California/04/2009(H1N1) and the
luciferase reporter gene. Neutralization activity was quantified by a relative decrease in the lu-
ciferase activity as compared to infection of 293A cells in the absence of sera based on previous-
ly described methods [16, 26]. A response was assessed as positive if the neutralization titer was
increased at least four fold above the pre-vaccination value.
Measurement of T-cell Responses
CD4 and CD8 T cell responses to H1 were assessed by intracellular cytokine staining (ICS) for
IL-2, TNF-α and IFN-γ, and by IFNγ ELISpot as previously described [27, 28]. Vaccine-in-
duced T cell responses were detected by ELISpot, using a commercially available ELISpot Kit
(Mabtech). Results were expressed as mean spot-forming cells (SFC) per million PBMC. A re-
sponse was considered to be positive if it met the following criteria: the number of spots per
1x106 cells minus the background exceeded 100 SFC/106 PBMC, and the non-background cor-
rected mean was at least four fold greater than the mean negative stimulation for the sample.
Vaccine-induced T cell responses were considered positive by ICS if the following criteria were
met: if a Fisher’s exact test for the 2x2 table consisting of positive and negative cells by peptide
and negative control had a one-sided p-value less than 0.01, and the percent positive cells for a
peptide minus the percent positive cells for the negative control (background subtracted per-
cent) exceeded the following: 0.05 for CD4 T cells, 0.08 for CD8 T cells (IFN-γ and TNF-α, and
0.05 for CD8 T cells (IL-2).
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Statistical Methods
Intention-to-treat analyses were applied for all endpoints. We reported the positive immunoge-
nicity response rates with the exact 95% confidence intervals from the Pearson-Clopper meth-
od. For the magnitude of immune responses, we reported the geometric mean for the antibody
response and the arithmetic mean for the T cell response along with the 95% confidence inter-
vals. All statistical analyses were performed using Statistical Analysis System (SAS) and R
statistical software. No formal multiple comparison adjustments were employed for safety end-
points or secondary endpoints.
Results
The IND for VRC-FLUDNA057-00-VP, a single plasmid DNA vaccine encoding the hemag-
glutinin (HA) protein of the 2009 pandemic A/California/09(H1N1) influenza, was submitted
by NIAID on July 9, 2009; this was 74 days after the U.S. declared the 2009 H1N1 pandemic in-
fluenza a public health emergency. The first DNA vaccination was administered on August 24,
2009, enrollment of 20 subjects was completed November 5, 2009, and all completed three H1
DNA vaccinations. The VRC 308 study timeline in relation to vaccine manufacturing and the
influenza pandemic is shown in Fig 1. A limited supply of licensed MIV became available for
distribution October 15, 2009 but was restricted to high-risk populations and health care work-
ers until more vaccine became available in January 2010. At that time, 18 subjects (1 subject re-
ceived MIV outside of the study and did not complete reactogenicity evaluations, but provided
blood for immunogenicity testing at the follow-up study visits) opted to receive MIV with the
resulting boost intervals ranging from 3 to 17 weeks after last H1 DNA injection. The last MIV
was administered February 17, 2010 and the last study visit was completed on June 17, 2010.
Study Population Demographics
Twenty healthy subjects between ages 24–70 years enrolled; 55% of study subjects were female.
Mean age of all subjects was 42 years and mean BMI was 25 (range from 20–38). Table 1 shows
demographic data and Fig 2 shows disposition of subjects.
Fig 1. Rapid DNA Vaccine Manufacturing in Response to Influenza Pandemic.
doi:10.1371/journal.pone.0123969.g001
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Vaccine Safety
The vaccine reactogenicity is summarized in Table 2. There were no vaccine-related serious ad-
verse events (SAEs) and no new chronic medical conditions reported; all AEs were mild or
moderate in severity. Four grade 1 adverse events were attributed as related to H1 DNA vaccine
Table 1. Baseline Characteristics of Participants.





Mean (std dev) 43 (16)
Range [22, 70]
Race—no (%)






Body mass index (BMI)
Mean (std dev) 25.5 (4.5)
Range [19.8, 38.3]
Education—no (%)
<High school graduate 0 (0)
High school/GED 2 (10)
College graduate 5 (25)
Advanced degree 13 (65)
doi:10.1371/journal.pone.0123969.t001
Fig 2. Consort Flow Diagram.Number of individuals assessed for eligibility, enrolled and followed up.
doi:10.1371/journal.pone.0123969.g002
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administration: a migraine at 5 days post vaccination and 3 cases of erosion at the site of injec-
tion at 2–7 days after vaccination. All of them were resolved without residual effects.
Two cases of influenza-like illness (ILI) were reported during the study: grade 1 ILI at 7 days
after the third H1 DNA administration, and grade 2 ILI at 6 days after MIV boost. Overall, vac-
cinations were well-tolerated and there was no severe reactogenicity reported.
Vaccine Immunogenicity
Immune responses to vaccination as measured by HAI, neutralization assay, ELISA and ELI-
Spot assay are summarized in Fig 3. Antibody responses were modest after DNA immunization
only, but in all cases, they improved after MIV boost. As evaluated by HAI, 6/20 (30%) of sub-
jects developed positive responses at 4 weeks after last H1 DNA, but the number rose to 13/18
(72%) at 4 weeks after the MIV boost. Similar results were detected in the neutralization
assay, 6/20 (30%) had positive response after H1 DNA injections, which rose to 15/18 (83%)
at 4 weeks post MIV boost. As measured by ELISA, only 4/20 (20%) of subjects developed posi-
tive responses at 4 weeks post last DNA, but 14/18 (78%) were positive 4 weeks after the MIV
boost.
As evaluated by ICS, CD4 T cell responses were more robust than CD8 responses. Prior to
vaccination, one subject had H1-specific CD8 T cells positive for IFN-γ and TNF-α, and one
subject had H1-specific CD4 T cells positive for IFN-γ. A statistically significant increase in the
magnitude of H1-specific T cell responses was observed at 4 weeks post last H1 DNA injection
as determined by ELISpot (Fig 3D. p = 0.0007). The magnitude and frequency of T cell re-
sponses was not increased by MIV boost (Fig 3). After H1 DNA alone, 5/20 (25%) of subjects
had a positive response, and only 3/18 (17%) subjects remained positive after the MIV boost.
Cumulative positive response rates by ICS for CD4 T cells were 50% for IFN-γ, 55% for IL-2,
and 60% for TNF-α. Cumulative CD8 T cell responses were less than 10% for all cytokines
tested.
Some subjects had pre-existing influenza responses as measured by HAI. 8/20 had positive
HAI response at baseline. 1/8 had a positive HAI response after DNA prime, compared to 5/12
that had negative baseline HAI responses. 3/7 had a positive HAI response after MIV, com-
pared to 10/11 that had negative baseline HAI responses.
Table 2. Frequency of Adverse Events.
H1 DNA x 3 (N = 20) H1N1 MIV (N = 17)
Any Solicited Local Reactogenicity—n (%)
None 1 (5) 15 (88)
Mild 18 (90) 2 (12)
Moderate 1 (5) 0 (0)
Severe 0 (0) 0 (0)
Any Solicited Systemic Reactogenicity—n (%)
None 5 (25) 12 (71)
Mild 12 (60) 4 (23)
Moderate 3 (15) 1 (6)
Severe 0 (0) 0 (0)
Solicited reactogenicity was collected for 7 days after each vaccination for 21 days total after H1 DNA
administered 3 times, and for 7 days after MIV administration. Each vaccine recipient is counted once at
worst severity for any local and systemic parameter.
doi:10.1371/journal.pone.0123969.t002
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Discussion
The investigational H1 DNA vaccine demonstrated the potential for rapid DNA vaccine pro-
duction in response to a pandemic. Vaccinations with the investigational H1 DNA vaccine
alone and when boosted with H1N1 MIV were safe and well tolerated. The H1 DNA vaccine
was immunogenic, but as a single agent demonstrated only modest immunogenicity. This find-
ing is consistent with our current understanding that the full effect of DNA vaccine priming on
immune responses may not be evident until boosting with an inactivated vaccine. Interpreta-
tion of immunogenicity results from this study is limited by the circumstances under which
this small Phase 1 study was conducted, which precluded inclusion of an MIV only control
group as a like-strain matched MIV was not available until 5 months after the study began. Ad-
ditionally, this study was not designed to compare responses to DNA or MIV vaccines between
subjects based upon the presence or absence of pre-existing influenza responses, and the num-
ber of subjects is too small to draw firm conclusions regarding this issue.
Immunogenicity significantly improved after MIV boost as measured by all vaccine induced
antibody-testing parameters. Consistent with findings in prior prime-boost studies [16, 29],
Fig 3. Immunogenicity. (A) Hemagglutination Inhibition (HAI) assay with A/Mexico/4482/2009 H1N1 virus (B) Neutralizing antibodies were evaluated by the
capacity of sera to prevent infection of 293A cells by replication-incompetent H1-pseudotyped virus. The 80% inhibition serum titers are shown. (C) End-point
ELISA titers of H1 A/California/04/2009(H1N1) specific antibodies are shown. Pre-vaccination titers have been subtracted from each plotted value. (D)
H1-specific T cell responses are shown as a number of spot forming cells (SFC) per 106 PBMC as measured by ELISpot assay. Geometric means and 95%
CI are shown for the study groups.
doi:10.1371/journal.pone.0123969.g003
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this finding suggests that the investigational DNA vaccine may be useful in a prime-boost regi-
men in combination with MIV. Other studies performed by our group since completion of this
study have demonstrated that the duration of the prime-boost interval is crucial in inducing
immunogenicity [16, 29]. An interval of 12, 18, or 24 weeks is ideal, while shorter intervals can
produce modest responses similar to what were seen in response to the H1 DNA vaccine alone.
Using another potential pandemic strain, H5 Indonesia/2005, a single dose of DNA primed ef-
fectively for an MIV boost given at an interval of at least 12 weeks [30, 31]. This finding was
consistent with work in other earlier vaccine trials, including studies with HBV vaccines [32,
33]. Further evaluation of samples from the H5 DNA study indicated that H5 DNA prime ex-
pands the antibody epitope repertoire and increases affinity maturation in a boost-interval-
dependent manner in adults [30, 32, 33]. Had a single dose of H1 DNA been utilized with a
12 week prime-boost interval, the overall regimen in the current study would have been short-
ened, and we postulate that immunogenicity would have been significantly improved. The
range of intervals between DNA prime and MIV boost was too wide for this study size to allow
for us to comment directly or conclusively on the effect of boost interval in the current study.
In contrast to the modest effect of DNA prime alone on antibody titers, the DNA plasmid vac-
cine induced statistically significant T cell responses in the absence of MIV boost, providing
measurable evidence that the DNA vaccine induced a priming effect.
Prior work with DNA vaccines has demonstrated improved immunogenicity with the use of
adjuvants and/or alternative delivery devices. In this trial, we use one such device, the Biojector,
which has been shown to improve immunogenicity of DNA vaccines [19]. Improved responses
have also been observed in human clinical trials when DNA vaccine is delivered by gene gun or
with electroporation or accompanied by adjuvants. [34–37] Perhaps in future trials, one of
these alternatives could be employed rather than MIV boost to further improve the immunity
induced by vaccination in a pandemic situation.
DNA plasmid and inactivated viral vaccines could be combined to improve overall protec-
tive immunity in response to an influenza pandemic. DNA plasmid vaccines have the advan-
tages of quick design and efficient production. While traditional methods of MIV production
depend upon incubation in chicken eggs, eventually producing approximately one dose per
egg, DNA plasmid vaccines can be produced using E. coli in bioreactors with capacity on the
order of thousands of liters. DNA plasmid vaccine design and production is not dependent on
selection for growth in chicken eggs, or even on cell culture, egg-free strategies. The overall pro-
duction endpoint is the ability to produce up to 1 million doses of a monovalent DNA vaccine
product within one month.
In a future pandemic setting, the speed of production of DNA plasmid vaccines could be
utilized to rapidly administer an initial priming dose. By the time a more traditionally pro-
duced, inactivated flu vaccine became commercially available, it could be used after 12 weeks
as a booster immunization. In such a regimen for a novel pandemic strain, inactivated viral
vaccine would be used only once as a boost, reducing the demand on production should yields
be low. A strategy harnessing the speed and efficiency of DNA plasmid production in combina-
tion with conventional MIV vaccine boosting has the potential to improve our response time
to new and emerging pandemic influenza threats.
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